Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.74 |
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.72 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HRH2 | P25021 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29977522 | 1.00 | TLR7 (0.74) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL29825771 | 0.91 | TLR7 (0.72) | TLR7TLR8NUDT1 | |
| SCHEMBL23360872 | 0.91 | TLR7 (0.72) | TLR7TLR8NUDT1 | |
| SCHEMBL23381040 | 0.91 | TLR7 (0.72) | TLR7TLR8NUDT1 | |
| SCHEMBL23381070 | 0.91 | TLR7 (0.72) | TLR7TLR8NUDT1 | |
| SCHEMBL23381156 | 0.90 | TLR7 (0.69) | TLR7TLR8NUDT1 | |
| SCHEMBL4053065 | 0.90 | TLR7 (0.69) | TLR7TLR8NUDT1 | |
| SCHEMBL23381089 | 0.90 | TLR7 (0.69) | TLR7TLR8NUDT1 | |
| SCHEMBL6726382 | 0.89 | TLR8 (0.72) | TLR7TLR8NUDT1 | |
| SCHEMBL3867963 | 0.89 | TLR7 (0.74) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230132111-A1 | PHARMACEUTICAL COMPOSITIONS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-04-27 | — | — | US | claimed |
| US-20210330664-A1 | PHARMACEUTICAL COMPOSITIONS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2021-10-28 | — | — | US | claimed |
| CN-110769827-A | Pharmaceutical composition | 博笛生物科技有限公司 | 2020-02-07 | — | — | CN | claimed |
| US-20040122231-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-24 | — | — | US | claimed |
| US-20030212270-A1 | Process for preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-c)quinolin-4-Amines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-11-13 | — | — | US | claimed |
| US-20030119861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-06-26 | — | — | US | claimed |
| US-20020115861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-08-22 | — | — | US | claimed |
| EP-0582581-B1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING & MFG (US) | 1999-05-06 | — | — | EP | claimed |
| US-5605899-A | VIRICIDES, BIOSYNTHESIS OF INTERFERONS, ANTITUMOR AGENTS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-02-25 | — | — | US | claimed |
| WO-1992015582-A1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-09-17 | — | — | WO | claimed |
| EP-3641771-B1 | COMPOSITIONS COMPRISING CRYSTALLINE RESIQUIMOD MONOSULFATE ANHYDRATE SALT OR OTHER RESIQUIMOD CRYSTALLINE SALTS OR OTHER CRYSTALLINE SALTS OF 1H-IMIDAZO-[4,5-C]-QUINOLINE DERIVATIVES FOR THE TREATMENT OF CANCER | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2026-05-13 | — | — | EP | disclosed |
| US-20250152703-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-15 | — | — | US | disclosed |
| US-12295950-B2 | Pharmaceutical compositions | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2025-05-13 | — | — | US | disclosed |
| US-12201684-B2 | Compositions for stimulation of mammalian innate immune resistance to pathogens | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240417738-A1 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | OHIO STATE INNOVATION FOUNDATION | 2024-12-19 | — | — | US | disclosed |
| US-5741909-A | PHARMACEUTICAL COMPOSITIONS WHICH ACT AS ANTIVIRAL AGENTS, INDUCE BIOSYNTHESIS OF INTERFERON AND INHIBIT TUMOR FORMATION IN ANIMALS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-04-21 | — | — | US | disclosed |
| US-5605899-A | VIRICIDES, BIOSYNTHESIS OF INTERFERONS, ANTITUMOR AGENTS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| US-5389640-A | Viricides, antitumor agents | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-02-14 | — | — | US | disclosed |
| EP-0582581-A1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO 4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-02-16 | — | — | EP | disclosed |
| WO-1992015582-A1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12295950-B2 | Pharmaceutical compositions | PLA2G2C, SFPQ, PRNP | TLR7 4767/4885TLR8 4832/4885NUDT1 346/4885 |
| US-20230132111-A1 | PHARMACEUTICAL COMPOSITIONS | PLA2G2C, SFPQ, PRNP | TLR7 4767/4885TLR8 4832/4885NUDT1 346/4885 |
| US-20030212270-A1 | Process for preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-c)quinolin-4-Amines | IFNAR1, IRF3, IFNG | TLR7 101/4885TLR8 382/4885NUDT1 58/4885 |
| US-20020115861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines | IFNAR1, IFNG, IRF3 | TLR7 54/4885TLR8 335/4885NUDT1 47/4885 |
| US-20040122231-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | UGT1A4, QARS1, HTR4 | TLR7 1287/4885TLR8 1825/4885NUDT1 118/4885 |
| US-20030119861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | IRF3, IFNAR1, IFNG | TLR7 105/4885TLR8 336/4885NUDT1 61/4885 |
| US-20210330664-A1 | PHARMACEUTICAL COMPOSITIONS | PLA2G2C, SFPQ, PRNP | TLR7 4767/4885TLR8 4832/4885NUDT1 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.